Why Aardvark Therapeutics (AARD) Paused Late-Stage ARD-101 Trials After Cardiac Findings

Key Takeaways

• Phase 3 ARD-101 trial paused due to QRS prolongation
• High dose: 2 of 8 showed >25% QRS rise
• Lower dose cohort also exhibited transient QRS changes
• Exposure‑response link suggests dose‑dependent cardiac risk
• $110 M cash reserves fund operations through Q2 2027

Summary

Aardvark Therapeutics announced on March 23, 2026 that it is voluntarily pausing its Phase 3 HERO trial of ARD‑101 for Prader‑Willi syndrome and the ARD‑201 obesity program while it consults the FDA. The decision follows cardiac findings in healthy‑volunteer studies, where participants receiving 1,600 mg twice daily showed QRS prolongation exceeding 25 % of baseline, and similar, transient changes appeared at 800 mg. The company expects guidance on the programs in Q2 2026 and reported $110 million in cash, sufficient through Q2 2027.

Pulse Analysis

Aardvark Therapeutics has positioned ARD‑101 as a first‑in‑class small‑molecule designed to curb hyperphagia in Prader‑Willi syndrome and obesity. By targeting the melanocortin‑4 receptor pathway, the drug promises to reduce uncontrolled appetite, a major unmet need in metabolic disease. The Phase 3 HERO study, along with an open‑label extension, represented the company’s most advanced clinical effort and a potential catalyst for a multi‑billion‑dollar market. Success would not only validate the therapeutic approach but also give investors a rare penny‑stock with high upside.

The pause stems from unexpected electrocardiographic changes observed in healthy volunteers. In the 1,600 mg twice‑daily cohort, two of eight participants experienced QRS prolongation exceeding 25 % of baseline, while a lower 800 mg cohort showed similar, albeit transient, alterations. Although the events were reversible and not classified as serious, the clear exposure‑response relationship raises red flags for regulators. The FDA will likely demand additional cardiac safety data, extending timelines and increasing development costs, which could dampen market enthusiasm for the drug’s launch.

Financially, Aardvark entered 2026 with roughly $110 million in cash, enough to sustain operations into the second quarter of 2027 under current burn rates. The trial suspension, however, introduces uncertainty that may pressure the stock’s valuation, especially as investors compare the risk profile to emerging AI‑focused equities. If Aardvark can resolve the cardiac signal and resume dosing, the upside remains significant given the scarcity of approved therapies for Prader‑Willi syndrome. Until then, stakeholders should monitor FDA feedback and any revised dosing strategies.